HC Wainwright Reaffirms Buy Rating for Werewolf Therapeutics (NASDAQ:HOWL)
HC Wainwright reiterated their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock. Separately, JMP Securities reduced their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating […]
HC Wainwright reiterated their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock. Separately, JMP Securities reduced their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating […]
